More than a year into a strategic pivot to zero in on the multiple myeloma cell therapy Abecma, 2seventy bio is selling ...

The EC has granted expanded approval to BMS' Breyanzi, to treat adults with relapsed or refractory follicular lymphoma (FL).

Bristol Myers Squibb (BMS) has received approval from the European Commission (EC) for its CD19-directed CAR T cell therapy ...

2seventy bio worked with BMS on the development of BCMA-directed CAR-T therapy Abecma (idecabtagene vicleucel), used to treat ...

The deal comes after a challenging few years for 2seventy bio, which had divested research programmes in recent years.

At one point, BMS said the facility would house 400 people. That was before Chairman and CEO Chris Boerner replaced Giovanni ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.

Bristol-Myers Squibb (NYSE:BMY) recently gained European Commission approval for Breyanzi, broadening treatment options for ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...